Omeros (NASDAQ:OMER) Upgraded by RODMAN&RENSHAW to “Strong-Buy” Rating

Omeros (NASDAQ:OMER) was upgraded by equities research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

OMER has been the subject of a number of other research reports. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a report on Thursday. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Thursday. StockNews.com cut shares of Omeros from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Rodman & Renshaw initiated coverage on Omeros in a research report on Thursday. They set a “buy” rating and a $9.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Omeros Stock Performance

OMER stock opened at $6.75 on Thursday. Omeros has a one year low of $1.38 and a one year high of $7.51. The stock has a market capitalization of $391.14 million, a P/E ratio of -2.92 and a beta of 1.47. The company has a 50 day moving average price of $4.08 and a two-hundred day moving average price of $4.07.

Institutional Investors Weigh In On Omeros

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets boosted its position in shares of Omeros by 75.5% during the 1st quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 12,951 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Omeros in the first quarter valued at approximately $85,000. Comerica Bank grew its stake in shares of Omeros by 20.0% during the first quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 5,000 shares during the period. Vanguard Group Inc. grew its position in shares of Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after buying an additional 81,348 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.